Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019
Collaborator: Bristol-Myers Squibb (BMS)
Authors: Wilczynski O, Boisbouvier A, Radoszycki L, Cotte FE, Gaudin AF, Lemasson H
Preserving the health related quality of life (HRQoL) of cancer patients is a major goal of clinicians and health authorities. By providing patients with a survival benefit and a better tolerance profile compared to therapeutic standards, immune-checkpoint inhibitors (ICI) treatment has become a therapeutic alternative in many tumor types. While the feasibility of collecting ICI-related symptom and HRQoL data is the subject of various studies, to understand patients’ and HCPs’ behaviors and expectations regarding HRQoL management in routine clinical practice becomes essential.
Objective: The study objective was to describe ICI-treated patients’ experiences and expectations regarding HRQoL consideration in cancer management.